Substrate Selection Influences Molecular Recognition in a Screen for Lymphoid Tyrosine Phosphatase Inhibitors

Zeitschriftenaufsatz


Autoren/Herausgeber


Forschungsfelder

Es wurden keine entsprechenden Inhalte gefunden.


Details zur Publikation

Autorenliste: Kulkarni RA, Vellore NA, Bliss MR, Stanford SM, Falk MD, Bottini N, Baron R, Barrios AM
Verlag: Wiley: 12 months
Jahr der Veröffentlichung: 2013
Bandnummer: 14
Heftnummer: 13
Erste Seite: 1640
Letzte Seite: 1647
Seitenumfang: 8
ISSN: 1439-4227
Sprachen: Englisch-Vereinigtes Königreich (EN-GB)


Beschreibung

Assay design is an important variable that influences the outcome of an inhibitor screen. Here, we have investigated the hypothesis that protein tyrosine phosphatase inhibitors with improved biological activity could be identified from a screen by using a biologically relevant peptide substrate, rather than traditional phosphotyrosine mimetic substrates. A 2000-member library of drugs and drug-like compounds was screened for inhibitors of lymphoid tyrosine phosphatase (LYP) by using both a peptide substrate (Ac-ARLIEDNE-pCAP-TAREG-NH2, peptide 1) and a small-molecule phosphotyrosine mimetic substrate (difluoromethyl umbelliferyl phosphate, DiFMUP). The results demonstrate that compounds that inhibited enzyme activity on the peptide substrate had greater biological activity than compounds that only inhibited enzyme activity on DiFMUP. Finally, epigallocatechin-3,5-digallate was identified as the most potent inhibitor of lymphoid tyrosine phosphatase activity to date, with an IC50 of 50 nM and significant activity in T-cells. Molecular docking simulations provided a first model for binding of this potent inhibitor to LYP; this will constitute the platform for ongoing lead optimization efforts.


Schlagwörter

Es wurden keine entsprechenden Inhalte gefunden.


Dokumente

Es wurden keine entsprechenden Inhalte gefunden.

Zuletzt aktualisiert 2019-23-08 um 11:15